Literature DB >> 17895753

Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: diagnostic and histogenetic implications.

Adam Kuehn1, Gladell P Paner, Brian F Skinnider, Cynthia Cohen, Milton W Datta, Andrew N Young, John R Srigley, Mahul B Amin.   

Abstract

Kidney-specific cadherin (Ksp-cad) is a membrane-associated cell adhesion glycoprotein expressed by the distal nephron tubular cells in its later developmental stages. Chromophobe renal cell carcinoma and renal oncocytoma are reported to be variably positive for Ksp-cad with some studies suggesting a discriminatory role for Ksp-cad. Immunoreactivity in other tumors with granular eosinophilic cytoplasm including clear cell and papillary renal cell carcinomas needs to be clearly elucidated and its expression in emerging novel and other unusual renal epithelial neoplasm subtypes including tumors with uncertain histogenesis is not yet known. In this study, we performed a detailed immunohistochemical analysis for Ksp-cad in a broad range of 136 renal epithelial neoplasms. Reactivity with Ksp-cad was observed in the following tumors: chromophobe renal cell carcinoma [23/25 (92%), diffuse (>50% of tumor cells)] positivity and membranous characteristically accentuating the "plant cell-like" histomorphology of the typical (clear) type, renal oncocytoma [15/20 (75%), usually diffuse staining with predominantly membranous accentuation], papillary renal cell carcinoma [5/17 (29%) all focal to moderate, eosinophilic type or type 2-3/7 (43%), basophilic type or type 1-2/10 (20%)], Xp11 translocation carcinoma [1/4 (25%), diffuse positivity] and clear cell renal cell carcinoma [6/36 (17%) all focal, clear cell renal cell carcinoma with prominent eosinophilic cells 1/7 (14%)]. Immunoreactivity was higher when evaluating whole histologic sections than with tissue microarrays for both chromophobe renal cell carcinoma (100% vs. 60%) and renal oncocytoma (100% vs. 55%). No immunoreactivity was observed in mucinous tubular and spindle cell carcinomas (0/23), high-grade collecting duct carcinomas (of Bellini) (0/3), renal medullary carcinomas (0/2), and urothelial carcinomas (0/6). Our study documents the immunoreactivity of Ksp-cad in the range of contemporarily classified renal epithelial neoplasms. The findings argue against the use of Ksp-cad in differentiating chromophobe renal cell carcinoma and renal oncocytomas and further support their relationship to the distal nephron. Ksp-cad may be helpful in distinguishing these two tumor types from clear cell renal cell carcinoma with prominent eosinophilic cells particularly in cases with limited tissue samples (ie, needle core biopsy). In the similar diagnostic setting, caution must be exercised, however, in differentiating chromophobe renal cell carcinoma and renal oncocytoma from the eosinophilic variant of papillary renal cell carcinoma as moderate expression of Ksp-cad may be observed in papillary renal cell carcinoma. The histogenesis of mucinous tubular and spindle cell carcinoma remains debatable as this tumor does not express Ksp-cad, which is highly expressed normally in the thick ascending loop of Henle and the distal convoluted tubules. In conclusion, Ksp-cad is a useful tumor type associated marker for distinguishing chromophobe renal cell carcinoma and renal oncocytoma from the wide range of nonintercalated cell-related adult renal epithelial neoplasms; addition of this marker to a panel comprised of other histologic subtype-associated markers may greatly facilitate histologic subclassification of adult renal epithelial neoplasms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17895753     DOI: 10.1097/PAS.0b013e318058818c

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  17 in total

1.  Tubulointerstitial nephritis without glomerular lesions in three patients with myeloperoxidase-ANCA-associated vasculitis.

Authors:  Kimimasa Nakabayashi; Ayumi Sumiishi; Katuko Sano; Yasunori Fujioka; Akira Yamada; Miho Karube; Hitoshi Koji; Yoshihiro Arimura; Toshihiko Nagasawa
Journal:  Clin Exp Nephrol       Date:  2009-06-09       Impact factor: 2.801

2.  Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.

Authors:  Pedram Argani; Jessica Hicks; Angelo M De Marzo; Roula Albadine; Peter B Illei; Marc Ladanyi; Victor E Reuter; George J Netto
Journal:  Am J Surg Pathol       Date:  2010-09       Impact factor: 6.394

3.  Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing.

Authors:  Gabriel G Malouf; Jianping Zhang; Ying Yuan; Eva Compérat; Morgan Rouprêt; Olivier Cussenot; Yunxin Chen; Erika J Thompson; Nizar M Tannir; John N Weinstein; Vicente Valero; David Khayat; Jean-Philippe Spano; Xiaoping Su
Journal:  Mol Oncol       Date:  2014-07-25       Impact factor: 6.603

4.  DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas.

Authors:  Gabriel G Malouf; Xiaoping Su; Jianping Zhang; Chad J Creighton; Thai H Ho; Yue Lu; Noël J-M Raynal; Jose A Karam; Pheroze Tamboli; Frederick Allanick; Roger Mouawad; Jean-Philippe Spano; David Khayat; Christopher G Wood; Jaroslav Jelinek; Nizar M Tannir
Journal:  Clin Cancer Res       Date:  2016-06-02       Impact factor: 12.531

5.  t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases.

Authors:  Nathaniel E Smith; Peter B Illei; Mohamed Allaf; Nilda Gonzalez; Kerry Morris; Jessica Hicks; Angelo Demarzo; Victor E Reuter; Mahul B Amin; Jonathan I Epstein; George J Netto; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

6.  Clear cell clusters in the kidney: a rare finding that should not be misdiagnosed as renal cell carcinoma.

Authors:  José-Antonio Ortiz-Rey; Carmen Fachal; Laura Juaneda-Magdalena; Mónica Muñoz-Martín; Alfredo Repáraz-Andrade; Susana Teijeira; José-María Lamas-Barreiro; Sheila Almuster-Domínguez; Pilar San Miguel-Fraile; Carolina Gómez-de María
Journal:  Virchows Arch       Date:  2021-01-14       Impact factor: 4.064

7.  Immunohistochemical application of S100A1 in renal oncocytoma, oncocytic papillary renal cell carcinoma, and two variants of chromophobe renal cell carcinoma.

Authors:  Naoto Kuroda; Naoki Kanomata; Tadanori Yamaguchi; Yoshiaki Imamura; Chisato Ohe; Noriko Sakaida; Ondrej Hes; Michal Michal; Taro Shuin; Gang-Hong Lee
Journal:  Med Mol Morphol       Date:  2011-06-30       Impact factor: 2.309

8.  Cadherin 17 is a sensitive and specific marker for metanephric adenoma.

Authors:  Evgeny Yakirevich; Cristina Magi-Galluzzi; Zakaria Grada; Shaolei Lu; Murray B Resnick; Shamlal Mangray
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

9.  BCA2 is differentially expressed in renal oncocytoma: an analysis of 158 renal neoplasms.

Authors:  Laleh Ehsani; Rishie Seth; Stephanie Bacopulos; Arun Seth; Adeboye O Osunkoya
Journal:  Tumour Biol       Date:  2012-12-15

10.  Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma.

Authors:  Sean R Williamson; John N Eble; Mahul B Amin; Nilesh S Gupta; Steven C Smith; Lynette M Sholl; Rodolfo Montironi; Michelle S Hirsch; Jason L Hornick
Journal:  Mod Pathol       Date:  2014-07-18       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.